Overview

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.
Phase:
Phase 4
Details
Lead Sponsor:
Handok Inc.
Handok Pharmaceuticals Co., Ltd.
Treatments:
Linagliptin